Navigation Links
Nektar Therapeutics Reports Second Quarter 2009 Financial Results
Date:8/4/2009

SAN CARLOS, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2009.

Net loss for the quarter ended June 30, 2009 was $32.1 million or $0.35 per share, compared to net loss of $33.4 million or $0.36 per share in the second quarter of 2008.

Nektar made improvements to its operating efficiencies as compared to a year ago. Total operating costs and expenses were down 19% to $43.5 million in the second quarter of 2009 as compared to $53.8 million in the second quarter of 2008. For the first half of 2009, total operating costs and expenses were down 28% to $83.5 million as compared to $115.6 million in the first half of 2008.

"In the first half of 2009, we made a strong commitment to advancing our clinical pipeline," stated Howard W. Robin, President and Chief Executive Officer of Nektar. "We completed our Phase 2 clinical program for NKTR-118, and we are poised to report Phase 2 data for NKTR-102 and Phase 1 data for NKTR-105 by year-end. These achievements underscore the strength of Nektar's drug development organization and our successful strategy to focus on developing proprietary drugs with our advanced polymer conjugate technology."

Research and development expense was $24.2 million in the second quarter of 2009 as compared to $33.5 million for the same quarter in 2008. For the first half of 2009, research and development expense was $48.0 million as compared to $70.9 million for the first half of 2008. Included in the $48.0 million of overall research and development expense in the first half of 2009 is approximately $27.4 million of investment in Nektar preclinical and clinical development programs.

Revenue for the three month period ende
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...ker.comannouncesthatanewmarketresearchreportisavai...s-AGlobalMarketReview ,, http://www.reportli...obal-Market-Review.html#utm_source=prnewswire&..., Cardiovascularmonitoringisextremelybeneficialfor...slymonitoredduringdiagnosticaswellaspatientcaresta...
(Date:11/23/2009)...ePointMedicalannouncedtodaythatitreceivedEuropeanC...ralChronicTotalOcclusion(CTO)CrossingSystemcompris...ray®CTORe-EntrySystem.TheBridgePointSystemisa...vigatehighlydiseasedarteriesinpreparationforbloodf...NationalHeart,LungandBloodInstitute(NHLBI)estimate...
(Date:11/23/2009)...- CryoLife,Inc. (NYSE: CRY ),animplantablebiologic...mpany,announcedtodaythatitisscheduledtoparticipate...renceatTheNewYorkPalaceHotelonDecember1,2009. ,...erofCryoLife,Inc.,willprovideacorporateoverviewreg...nandanswersessionat4:30p.m.EasternTime. ,, Cryo...
Breaking Medicine Technology:Reportlinker Adds Holter Monitoring Systems - A Global Market Review 2Reportlinker Adds Holter Monitoring Systems - A Global Market Review 3Reportlinker Adds Holter Monitoring Systems - A Global Market Review 4Reportlinker Adds Holter Monitoring Systems - A Global Market Review 5BridgePoint Medical(R) Receives European CE Mark for Stingray(R) and CrossBoss(TM) for Opening Completely Blocked Arteries 2CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference 2Anthem Blue Cross in California Provides More Members With Access to Comprehensive Transparency Tool 47846 1Anthem Blue Cross in California Provides More Members With Access to Comprehensive Transparency Tool 47846 2Anthem Blue Cross in California Provides More Members With Access to Comprehensive Transparency Tool 47846 3Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference 12455 1Sangamo BioSciences Announces Presentation at the Needham Life Sciences Conference 12455 2IMAGINE Software Unveils Advanced IMAGINEradiology 28TM 29 Features 47841 1IMAGINE Software Unveils Advanced IMAGINEradiology 28TM 29 Features 47841 2
...rom Phase 1a SAD Clinical Study -, BRISBANE, Cali...ounced that the company has begun dosing the first...e (MAD) clinical trial,evaluating ITMN-191 (also c... ITMN-191 is a hepatitis C virus (HCV) protease in...r, Roche. InterMune also reported additional,infor...
... 1 Clinical Development for the Treatment of ...ARLOS, Calif., Sept. 26 Nektar,Therapeutics (Nasd...rom Phase,1 and preclinical studies of NKTR-118 (o...anagement (AAPM) meeting in Las Vegas, Nevada. NKT...tudied for its potential to treat,patients sufferi...
Other Medicine Technology:InterMune Announces Start of Phase 1b Trial of ITMN-191 2InterMune Announces Start of Phase 1b Trial of ITMN-191 3InterMune Announces Start of Phase 1b Trial of ITMN-191 4Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 2Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 3Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 4Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 5
(Date:11/23/2009)...OKEN, N.J. The Center for Science Writings at Ste...lution of God," a talk by Robert Wright, journalis...er 2, 2009, 4:00-5:30 p.m. at the Babbio Center fo...ee and open to the public and the media., In his...journalist Robert Wright, renowned for his popular...
(Date:11/23/2009)...ARLINGTON, Va. The Infectious Diseases Society of...e Obama administration and the European Union to f...pment of 10 new antibiotics within the next 10 yea...ealth Organization (WHO) has identified antimicrob...s to human health. , A new European Union report...
(Date:11/23/2009)... iCRco is proud to announce it... KLAS and received the highest grade possible amon...ufacturer to be rated “A” in sales, se...stomer satisfaction in software functionality. iCR...hest grade by the most prestigious research firm i...
(Date:11/23/2009)..., ALEXANDRIA,Va.,Nov.23/PRNewswire/--Justintimefo...ovideshomechefswithtipsandrecipesforcookingupadeli...gcurrentnewsandhealthinformation, turkeyfrying.ne...nfriedturkeyaswellaspartyideasfortakingtheturkeybe...eauthenticallySouthernwayofdeep-fryingwith100%pean...
(Date:11/23/2009)...t says findings support link between mental and ph...hDay News) -- Being depressed might take as many y...ggests. , However, a combination of depression ...n just depression. , Researchers came to their ...rvey of more than 60,000 people. During the four y...
Breaking Medicine News(10 mins):Health News:10 x '20: ID experts call for 10 new antibiotics by 2020 2Health News:10 x '20: ID experts call for 10 new antibiotics by 2020 3Health News:iCRco is the Only CR Vendor to Receive the Highest Grade “A” in All Fields by KLAS 2Health News:iCRco is the Only CR Vendor to Receive the Highest Grade “A” in All Fields by KLAS 3Health News:Depression May Up Death Risk to That of Smoking 2
...ational AIDS Control Organisation with support fro...and National Institute of Medical Statistics (ICMR...ng high-risk populations, STI patients and Antenat...revalence among antenatal mothers has been observe...
...nly used drugs that are used in treatment of cance... determined by a research, published by the Journa...therapy can result in brain damage. The effects ma... patients. Cancer survivors, even after months hav...
...rug Controller General of India has recently appro...atment of Kala-azar patients.// The clinical ...ted by Indian Council of Medical Research, New Del... first line of treatment. The Government o...
...e are becoming exceedingly health conscious thus t...cohol among the UK population. It’s a known fact t...risk of heart ailments but it’s not very safe for ... My recommendations are for moderate drinking – wi...
...er Nancy Burton of Mount Maunganui, who faced char...prescription items has been found guilty .The tria...tion was conducted by the Ministry of Health and t...he Bay of Plenty District Health Board. Quen...
...oluntary Counseling and Testing (VCT) program in S... financial year between April 2005 and March 2006,... people tested has almost doubled as compared to l...among those who were tested were found to be HIV p...
Other Medicine News:
Body Suit w/Bra knee length
Compression Vest V-640
Male Compression Vests
Female Compression VEST w/sleeves
Medicine Products: